Browsing Clinical Studies by subject "MAP Kinase Signaling System"

Now showing items 1-6 of 6

Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.

Li, S; Fong, K-W; Gritsina, G; Zhang, A; Zhao, JC; Kim, J; Sharp, A; Yuan, W; Aversa, C; Yang, XJ; Nelson, PS; Feng, FY; Chinnaiyan, AM; de Bono, JS; Morrissey, C; Rettig, MB; Yu, J (2019-05)

Castration-resistant prostate cancer (CRPC) that has developed resistance to the new-generation androgen receptor (AR) antagonist enzalutamide is a lethal disease. Transcriptome analysis of multiple prostate cancer models ...
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.

Fisher, R; Horswell, S; Rowan, A; Salm, MP; de Bruin, EC; Gulati, S; McGranahan, N; Stares, M; Gerlinger, M; Varela, I; Crockford, A; Favero, F; Quidville, V; André, F; Navas, C; Grönroos, E; Nicol, D; Hazell, S; Hrouda, D; O'Brien, T; Matthews, N; Phillimore, B; Begum, S; Rabinowitz, A; Biggs, J; Bates, PA; McDonald, NQ; Stamp, G; Spencer-Dene, B; Hsieh, JJ; Xu, J; Pickering, L; Gore, M; Larkin, J; Swanton, C (2014-08-27)

<h4>Background</h4>Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution.<h4>Results</h4>We perform whole exome sequencing ...
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Hall, E; Banerji, U
Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Fultang, L; Gamble, LD; Gneo, L; Berry, AM; Egan, SA; De Bie, F; Yogev, O; Eden, GL; Booth, S; Brownhill, S; Vardon, A; McConville, CM; Cheng, PN; Norris, MD; Etchevers, HC; Murray, J; Ziegler, DS; Chesler, L; Schmidt, R; Burchill, SA; Haber, M; De Santo, C; Mussai, F (2019-02)

Neuroblastoma is the most common childhood solid tumor, yet the prognosis for high-risk disease remains poor. We demonstrate here that arginase 2 (ARG2) drives neuroblastoma cell proliferation via regulation of arginine ...
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.

Ang, JE; Pal, A; Asad, YJ; Henley, AT; Valenti, M; Box, G; de Haven Brandon, A; Revell, VL; Skene, DJ; Venturi, M; Rueger, R; Meresse, V; Eccles, SA; de Bono, JS; Kaye, SB; Workman, P; Banerji, U; Raynaud, FI (2017-10)

MAPK pathway activation is frequently observed in human malignancies, including melanoma, and is associated with sensitivity to MEK inhibition and changes in cellular metabolism. Using quantitative mass spectrometry-based ...
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.

Bridgeman, VL; Wan, E; Foo, S; Nathan, MR; Welti, JC; Frentzas, S; Vermeulen, PB; Preece, N; Springer, CJ; Powles, T; Nathan, PD; Larkin, J; Gore, M; Vasudev, NS; Reynolds, AR (2016-01)

Sunitinib and pazopanib are antiangiogenic tyrosine kinase inhibitors (TKI) used to treat metastatic renal cell carcinoma (RCC). However, the ability of these drugs to extend progression-free and overall survival in this ...

Publications Repository

Publications Repository

Browsing Clinical Studies by subject "MAP Kinase Signaling System"

Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.

Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.

Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.

Browsing Clinical Studies by subject "MAP Kinase Signaling System"

Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. ﻿

Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. ﻿

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study ﻿

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma. ﻿

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. ﻿

Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. ﻿

Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.

Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma.

Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.